Comparing Orthofix Medical (NASDAQ:OFIX) and Echo Therapeutics (OTCMKTS:ECTE)

Orthofix Medical (NASDAQ:OFIX) and Echo Therapeutics (OTCMKTS:ECTE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Valuation & Earnings

This table compares Orthofix Medical and Echo Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orthofix Medical	$822.31 million	0.56	-$92.19 million	($2.34)	-4.93
Echo Therapeutics	N/A	N/A	N/A	N/A	N/A

Echo Therapeutics has lower revenue, but higher earnings than Orthofix Medical.

Profitability

This table compares Orthofix Medical and Echo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orthofix Medical	-11.21%	-20.38%	-11.03%
Echo Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for Orthofix Medical and Echo Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orthofix Medical	1	2	3	0	2.33
Echo Therapeutics	0	0	0	0	0.00

Orthofix Medical presently has a consensus price target of $17.25, suggesting a potential upside of 49.61%. Given Orthofix Medical’s stronger consensus rating and higher possible upside, equities analysts clearly believe Orthofix Medical is more favorable than Echo Therapeutics.

Institutional & Insider Ownership

89.8% of Orthofix Medical shares are owned by institutional investors. 1.3% of Orthofix Medical shares are owned by insiders. Comparatively, 7.0% of Echo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Orthofix Medical beats Echo Therapeutics on 5 of the 9 factors compared between the two stocks.

About Orthofix Medical

Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.

About Echo Therapeutics

Echo Therapeutics, Inc. is a medical device company, which engages in the development of non-invasive, and wireless continuous glucose monitoring system for use in the diabetes outpatient market. It offers needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose and delivery of topical pharmaceuticals. The company was founded in 1989 and is headquartered in Iselin, NJ.